Latest News from Gb Sciences
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences’ COVID-19-Related, Anti-Inflammatory Therapies
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
Gb Sciences to Begin Dosage Study for Its Novel Parkinson’s Disease Formulations at the University of Lethbridge
As seen on Worldwide Business with Kathy Ireland
Choose Your Area Of Interest
GBLX’s novel drug discovery program produced 6 issued US and 3 issued international patents, as well as 18 US and 49 international patent-pending applications. We have 5 preclinical phase drug programs in our pipeline, and our Parkinson’s therapeutics are being prepared for a First-in-Man trial.
The strength of our R & D pipeline has been the participation of world class researchers from 9 international universities over the past 7 years. Together, we have assembled the ultimate toolkit to create the future of medicine; AI technology, plant-based medicine, and hard sciences.
Translating new drug principles into real world medicines requires expertise in several disciplines. Our partners help make our dream of novel plant-inspired medicines a reality by providing expertise in cGMP-certified active ingredients and novel oral delivery methods.
NEXT GENERATION PLANT-INSPIRED MEDICINE
Our Goal is to preserve the efficacy of plant-based medicines while reducing their complexity for standardization.
Our Strategy is to combine our proprietary PhAROS Drug Discovery Platform and High Throughput Screening of Cell and Animal Models of Specific Disease Processes to Create Rationally-Designed, Minimum Essential Mixtures.
Here are the latest articles
by Gb Sciences.
Andrea Small-Howard, Ph.D.